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Introduction The aim of this study was to examine the aspect of information disclosure by 
doctor-investigator during the process of obtaining informed consent in 
clinical trials.
Methods This research employed a mixed-method data collection that is library 
research and interview. A qualitative methodology and analysis were used in 
an open-ended, face-to-face interviews with 17 patient-subjects. The 
interview questions were based on information that needed to be disclosed to 
patient-subjects during the process of obtaining informed consent. Each 
interview took place in Kajang Hospital and National Heart Institute and 
lasted 25-30 minutes. Interviews were conducted in Bahasa Melayu and 
English. The interviews were tape-recorded, and the main points from the 
interviews were jotted down to ensure that all information was adequately 
gathered. Interviewed occurred in Kajang Hospital and National Heart 
Institute. The participants were patients who had been referred to the Kajang 
Hospital and National Heart Institute. They were recruited (8 from Kajang 
Hospital and 9 from National Heart Institute) by their own doctors to 
participate in a study to evaluate the safety and effectivenes of the 
investigational stent after been diagnosed with coronary artery disease and 
also in a study to investigate drug for antidepressant. respectively.
Results The study revealed that doctor-investigators fail to disclose full information 
to patient-subjects. Instead, doctor-investigators only disclosed information 
which they thought were necessary for the patient-subjects to know. The 
study also showed that there were doctor-investigators who did not disclose 
information at all to the patient-subjects.
Conclusions This study implies that the aspect of information disclosure in the process of 
obtaining informed consent in clinical trials is rather poor and did not fulfill 
the criterion of good medical practice. A random monitoring task to be 
conducted by the research ethics commitees during the informed consent 
process is suggested.
Keywords Informed consent - Clinical trials - Patient-subjects - Doctor-investigators -
Process - Information.
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INTRODUCTION
In clinical trials, patient-subjects ‘voluntarily’ 
accept the risks inherent in a trial for the benefit of 
future patients and not themselves. This is because 
clinical trials focus on creating an overall 
knowledge for the benefit of future patients, a 
process requiring the doctor-investigator to conduct 
trial according to a protocol and not according to 
what is individually best for the patient-subject1. 
Previous experience too has demonstrated that 
patient-subjects cannot rely on the beneficence of 
doctors in the clinical trials arena2. In fact, a breach 
of duty that leads to negligence in clinical trials 
often occur due to failure of doctor-investigators to 
disclose full information to enable patient-subjects 
to give consent to participate in the clinical trials3. 
Therefore, the need to obtain patient-subjects’ 
consent by way of informed consent has been made 
compulsory to justify the patient-subjects’ 
recruitment in clinical trials4. Informed consent in 
clinical trials has been demarcated in general as a 
negotiation or communication process between the 
doctor-investigator and the patient for the purpose 
of obtaining the patient’s consent to participate in 
the trial. The doctor-investigator must disclose full 
information about the trial during this process, 
among them are the objective of the trial, purpose 
of the trial, procedures of the trial, alternative 
methods available, probable benefits and risks, the 
possibility of being randomised and that the 
patient’s involvement is voluntary whereby the 
patient can withdraw from the study whenever he 
wanted without jeopardizing his current or future 
treatment5.
Informed consent implies that 
participation is voluntarily. As such, doctor-
investigator must ensure that the patient-subject 
knows the implications of participation. Even if a 
patient-subject has signed an informed consent 
form, the patient-subject does not necessarily 
understand what the participation will entail, and 
consent thus may not be informed6. The question is, 
to what extent the patient-subject needs to know in 
order to be ‘informed’? According to Roth et al.,7 
the  ‘knowing’ prong needs the doctor-investigator 
to make full disclosure of the purpose, procedure, 
and risk and benefits of the study. Morin8 shared a 
similar view when she said that, “[o]nly a distinct 
and strict rule on full disclosure can protect the 
principle of autonomy of human research 
subjects.” Thus, this leads to another question to 
ponder as to what is meant by ‘full disclosure of 
information’?
In the case of R v Mental Health Act 
Commission ex parte X (orse W) (1988) 9 BMLR 
77, Judge Stuart Smith states that, “no doubt 
consent has to be ‘informed consent’ in that [the 
patient] knows the nature and likely effects of the 
treatment”. In this case, when the anti-cancer drug
(goserelin) has been used to restrain sexual desire, 
the learned judge decided that it was significant for 
the patient to know about this. However, he 
rejected the proposition that, “a patient must 
understand the precise physiological process 
involved before he can be said to be capable of 
understanding the nature and likely effects of the 
treatment or can consent to it.” According to him, 
the patient does not need to know in detail all the 
processes involved.
Hence, based on the above decision, the 
researchers submitted that a full disclosure of 
information in clinical trials means that the doctor-
investigator must disclose all information 
particularly the risks. However, a detail 
information on how the risks will occur need not to 
be disclosed to patient-subjects. For example, in 
stent procedure patient needs to go through an 
angiogram, where doctor-investigator will place a 
small thin tube in the patient’s arm or leg to inject 
an x-ray dye into his blood vessel so the narrowing 
of the blood vessel can be easily seen under special 
x-rays. Patient may a feel warm sensation during 
the angiogram, which is caused by the x-ray dye. 
This warm sensation usually passes after a short 
time. All this information needs to be disclosed to 
patient but the detail information on how the warm 
sensation process occurs need not to be disclosed. 
Unfortunately, many studies have shown 
that doctor-investigators failed to disclose full 
information to patient-subjects. Patient-subjects 
were not told the aim of the trial, its methodology, 
potential risks or anticipated benefits of treatment9. 
A study by Titus dan Keane as cited by Hall10 who 
studied 167 principal investigators applying to 
Midwestern review boards for approval for a range 
of research studies, including clinical trials, drug 
and device studies indicated that only one-third of 
the investigators gave a detailed description of the 
purpose and procedure of their study, but 
meaningful discussion of all other areas, including 
risks, benefits and alternatives were almost non-
existent; eighty percent demonstrated that they 
relied wholly on asking close-ended questions, 
precluding any form of dialogue with the patient; 
few of the researchers appeared to have any 
appreciation of the need to assess potential 
subject’s understanding of what they had been told. 
Meanwhile, in a study investigating the effects of 
different drugs in 43 women with acute salpingitis, 
five were not aware that a second laparoscopy was 
performed only for research purposes. Seven 
women stated that they had not been aware of the 
meaning of participating in the study and 17 
women did not know that they could withdraw 
from the study whenever they wanted11.
In Malaysia, until today there is no study 
conducted on the aspect of information disclosure 
by doctor-investigator. However, this does not 
mean doctor-investigators in Malaysia do not 
practice disclosing full information. This is mainly 
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due to the fact that Malaysian society, specifically 
the patients, place great trust on their doctors. As 
such, doctors do not disclose full information to 
them.  In support of this view, reference can be 
made to the points put forward by Puteri Nemie 
Jahn Kasim & Mohamad Akram Shair Mohammad
in the book titled Issues in Medical Law and 
Ethics. The authors stated that, “The main problem 
for patients in Malaysian hospital is that their 
consent has rarely been ‘informed’ in nature. They 
are usually asked to sign consent forms before any 
operation but in reality, they do not really 
understand what they are signing. They are rarely 
informed about the risks inherent in any proposed 
treatment.” 12 For instance, in the case of Tan Ah
Kau v Government of Malaysia (1997) 2 AMR 
1382, the court held that no consent was actually 
given by the plaintiff, as the nature of such 
operation had not fully and comprehensively 
explained to the plaintiff. Unfortunately, there is no 
literature or case to support that patient-subjects 
also put high hope on ‘doctor’ in clinical trial as in 
medical treatment. However, the researchers were 
of the opinion that a similar attitude occurs. This 
opinion can be supported by quoting the words of 
Dr. Suhaini Kadiman: “Based on our experience if
the consent is taken by the ‘doctor’ the chances of 
recruitment is higher because of trust and confident 
to ‘doctor’ compared to consent taken by a third 
party for example a health care personnel” 13. 
Hence, the aim of this study is to examine the 
aspect of information disclosure by doctor-
investigator during the process of obtaining 
informed consent in clinical trials.
METHODS
This research applies a mixed-method data 
collection that is library research and interview.
Qualitative methodology and analysis were used in 
open-ended, face-to-face interviews with 17 
patient-subjects. Fourteen semi-structured 
questionnaires were administered to the patient-
subjects during the interview. The interview 
questions were based on information that needed  
to be disclosed to patient-subjects during the 
process of obtaining informed consent. Only 17 
patient-subjects interviewed due to doctor-
investigators’ refusal in allowing their patient-
subjects to participate. The participants were 
patients who had been referred to the Kajang 
Hospital and National Heart Institute. They were 
recruited (eight from Kajang Hospital and nine
from National Heart Institute) by their own doctors 
to participate in a study to evaluate the safety and 
effectivenes of the investigational stent after been 
diagnosed with coronary artery disease and are 
scheduled to undergo coronary stent placement and 
in a study to investigate drug for antidepressant. 
respectively. Patient-subjects involved 10 males 
and seven females from the ages of 20 to 60. They 
were government servants as well as private 
employees, pensioners and a college student. Since 
the researchers were not the doctor-investigators 
who must obtain signed informed consent from the 
patient-subjects in order to be enrolled in the trial, 
the patient-subjects’ consent were only taken orally 
after being informed that the data collected were 
for academic purposes. Upon the advice from the 
National Institutes of Health, online registration 
was made with the National Medical Research 
Register in seeking permission to conduct 
interview pursuant to the Director of Health 
Circular No. 9/2007. The registration involved the 
submission of the proposal of the study and the 
questionnaires of the interview to be considered for 
approval. A letter in seeking permission to conduct 
interview was also send to the Medical Director of 
National Heart Institute. Each interview took place 
in Kajang Hospital and National Heart Institute and 
lasted 25-30 minutes. Interviews were conducted in 
Bahasa Melayu and English. The interviews were 
tape-recorded, and the main points from the 
interviews were jotted down to ensure that all 
information was adequately gathered. It was also 
important to capture the verbal and non-verbal 
reaction of the officers during the interview.
RESULTS
Out of the 17 patient-subjects interviewed on 
whether doctor-investigators performed informed 
consent process, 12 answered ‘Yes’ and five
answered ‘No’. Answers given by patient-subjects 
saying that no informed consent process was held 
by doctor-investigators were described below and 
illustrated with verbatim quotes from patient-
subjects.
Table 1 Lists of answers given by patient-subjects saying that no informed consent process was held by doctor-
investigators
No. Answers
1. “The research nurse said that there will be a study to try a new drug only. I read the form ... 
but there was not much explanation given ... if I agree I can participate. During the process of 
obtaining the consent no explanation was given as she was in a hurry. She said that if I agree 
to participate I can sign but if not I need not to sign.”
2. “He [doctor-investigator] took for granted because we have read through already ... Doctor 
should try to explain as much as possible.”
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3. “Doctor said, after undergoing the angiogram procedure, there will be a stent procedure 
because my blood vein was 90% blocked ... cannot insert balloon [balloon catherer process] 
anymore. I thought it was a normal procedure for my treatment and not a study”.
4. “There was no explanation session pertaining to the study [informed consent process]. The 
doctor only told me about trying a new drug in the OT  room before undergoing the 
angiogram procedure. I ask for postponement but the doctor objected the postponement. He 
said that this study [the stent procedure] is good. This is a study to investigate whether it will 
work better or as good as the current one, it will not be lesser than the current one but it will 
be better.”
5. “The doctor only told me to sign the release form for survey purpose.”
When the researchers asked about 
information dissemination, all 12 patient-subjects 
confirmed that the doctor-investigators have 
conducted the informed consent process. They 
added that the doctor-investigators have informed 
them of the background of the study, the purpose of 
the study and the fact that there is nothing wrong 
with the current treatment. They also confirmed 
that the doctor-investigator had informed them that 
he wanted to try a new drug. However, when 
researcher asked whether doctor-investigator had 
disclosed on the probable benefits and risks of the 
study, only nine answered ‘Yes’ while eight
answered ‘No’.
All of the 12 patient-subjects answered 
‘No’ to the question of whether they were informed 
about the possibility of being randomized. The 
researchers also found out that all of them did not 
even understand the meaning of randomization in 
clinical trials. 
When asked whether the  doctor-
investigators disclosed to them that their 
participation were voluntary and that the patient-
subjects can participate or withdraw from the trial 
at any time without jeopadizing their current and 
future treatment, all of the 12 patient-subjects 
answered ‘Yes’. However, one patient-subject said 
that even though  the  doctor-investigators 
informed him that his participation is voluntary, he 
failed to explain in detail that he (the patient-
subject) was free to accept or withdraw from the 
trial at any time without jeopardizing his current or 
future treatment. The patient-subject said, “Only 
informed that you [the patient-subject] has been 
chosen ... not everybody can get this opportunity ... 
this is why motivate me to participate.”
Relating to the question of whether 
patient-subjects were given the chance to ask 
questions about the trial, 10 patient-subjects 
answered ‘Yes’ while two answered ‘No’. 
However, when the reseachers asked whether 
doctor-investigators gave adequate time to give 
consent, all of the 12 patent-subjects answered 
‘Yes’. Nevertheless, according to one patient-
subject, he signed the consent form in a hurry as he 
was about to be discharged from the hospital and 
the distance from his house to the hospital was far. 
In addition, according to another patient-subject, 
the doctor-investigator invited him to participate in 
the trial when he was in pain in the ‘Coronary Care 
Unit’ (CCU) and since the doctor-investigator was 
in a hurry so he only read the information which he 
thought was important.
When they were asked whether their own 
doctor had conducted informed consent process, all 
of the 12 patient-subjects answered ‘Yes’. Next, 
when asked whether they felt obliged to participate 
as their own doctors have invited them, all of the 
12 patient-subjects answered ‘No’. However, the 
patient-subjects gave the following answers:
i) “I always felt exhausted, doctor said I can 
try the drug [study drug] can get rid of my 
exhaustion ... so I try” 
ii) “I am sick ... doctor suggested we have to 
accept it ... we cannot reject his invitation. 
As a doctor of course he will suggest only 
the best for his patient. Although we do 
not know but he is a doctor. A doctor will 
not give poison ... I am not being forced to 
participate in the study but since the 
doctor wanted to make a study we have to 
follow ... we want to get well”. 
iii) “He [doctor] said that the study drug can 
help me ... the medicine I have been taken 
before is quite expensive so he offered me 
to take the new medicine ... to participate 
in the study and to help me financially” 
iv) “I had a heart attack when he invited me 
to join the trial.”
v) “The doctor informed me that if I want the 
drug, I have to join the trial. 
vi) “Doctor said that the previous medication 
had many side effects, the new ones have 
lesser side effects so that’s why I join ... to 
be cured.” 
vii) “Doctor said can get well if I join”
When the reseachers asked whether they 
understood all the information disclosed by the 
doctor-investigators, all of the 12 patient-subjects 
answered ‘Yes’. However, a few of them said that 
the form was too long and that they only read the 
information that they felt important. Other 
comments included, the doctor-investigators were 
in a hurry, informed consent process were 
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conducted while they were in the CCU ward and 
while they were about to be discharged from the 
hospital.
When asked whether their relatives were 
present during the informed consent process being 
held, 10 patient-subjects answered ‘Yes’ while two
answered ‘No’. One of the patient-subject 
answered ‘No’ as he was in CCU ward during that 
time. Table 2 below shows the results of informed 
consent process.
Table 2 Questions and results of patient-subjects regarding the informed consent process
Yes No
Was information on the trial given to you before you signed the consent 
form?
12 5
If yes, did you understand the information given? 12 0
Did your doctor conducts informed consent process? 12 0
If yes, did you feel oblige to accept his invitation? 0 12
Were your relatives present during the informed consent process being 
held?
10 2
Were you informed about the background of the study? 12 0
Were you informed about purpose of the study? 12 0
Were you informed that currently you are receiving the ‘best current 
proven treatment’, meaning that there is no problem with it but it is just 
that the doctor wants to try a new drug?
12 0
Were you informed about the procedure(s) of the study? 12 0
Were you informed about the probable benefits and risks of the study? 9 8
Were you informed about the possibility of being randomized? 12 12
Were you given the chance to aks questions pertaining to the trial? 11 1
Were you given enough  time to make decision? 12 0
Did you voluntarily participate in the trial? 12 0
DISCUSSION
The present study explored the process of obtaining 
informed consent in clinical trials in Malaysia. The 
results of this study revealed that the doctor-
investigators fail to disclose full information to 
patient-subjects. Instead, the doctor-investigators 
only disclosed information which they thought 
were necessary for the patient-subjects to know. 
The study also showed that there were doctor-
investigators who did not disclose information at 
all to the patient-subjects. In other words, no 
informed consent process were conducted. The 
results of this study were not suprising as similar 
results was revealed by previous studies as 
mentioned earlier.
The results demonstrated that doctor-
investigators in Malaysia practiced medical 
paternalism similar to doctor-investigators around 
the world. The strong desire to obtain a new 
scientific knowledge ‘ethos of science’ has led 
some doctor-investigators to deliberately ignore the 
patient-subjects’ protection through informed 
consent. In a study at the National Women’s 
Hospital in Auckland, New Zealand a researcher, 
Associate Professor Herbert Green, believed that 
‘carcinoma in situ’ [CIS] left untreated, would not 
lead to invasive cancer of the cervix. To test his 
proposition (which was against the international 
opinion at the time) conventional treatment was 
withheld from some of the women diagnosed with 
CIS, who were then observed for signs of 
progression of their disease. Those in the treatment 
group received normal treatment (essentially 
removal of suspect tissue). However, many more 
women in the ‘non-treatment’ group advanced to 
the  invasive stage. An official inquiry headed by 
Judge Silvia Cartwright found that at least 27 on 
the non-treatment group had died unnecessarily and 
many suffered the consequences of their disease for 
years without ever being informed of their initial 
diagnosis. Green maintained that, it was not in the 
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women’s interests to tell them about what he was 
doing. Patients he said, “were unnecessarily 
frightened if they heard the word cancer, and 
should be protected from doctors’ uncertainties”14.
In 1997, a research involving HIV testing of all 
patients’ admitted to intensive care units in Durban 
for diseases unrelated to HIV, this was done 
without the patients’ prior knowledge or consent. 
Part of the researchers’ rationale was that it was 
essential not to inform the patients since, “patients 
who were likely to be at risk for HIV infection 
would also be inclined to refuse the study, which 
would seriously limit its value.” Also in 1997, a 
cervical cancer study in India, commissioned by 
the Indian Council of Medical Research, excluded 
any requirement for informing the participants of 
their risk of developing cancer. The researchers 
argued that the women participating in the study 
were illiterate and obtaining informed consent 
would be impossible15.
Nevertheless, the researchers were of the 
opinion that the attitude of the patients-subjects that 
placed high hopes on doctor-investigators has 
indirectly encouraged the latter not to disclose 
information by adopting the principle of 
therapeutic privilege, a practice seen in the normal 
doctor-patient relationship. This act of paternalism 
has been brought into the process of consent taking 
in clinical trials. The special relationship that exist 
between ‘doctor’ and patient has led patients to 
believe and feel confident that the ‘doctor’ will act 
in their best interest. Hence, in general the patient 
does not ask the ‘doctor’ for information. In 
addition, the fact that ‘doctors’ have greater 
medical knowledge also caused patient-subjects to 
rely on them to make decision. This opinion can be 
supported by quoting one of the patient-subjects 
answer: “I am sick ... doctor suggested we have to 
accept it ... we cannot reject his invitation. As a 
doctor of course he will suggest only the best for 
his patient. Although we do not know but he is a 
doctor. A doctor will not give poison ... I am not 
being forced to participate in the study but since 
the doctor wanted to make a study we have to 
follow ... we want to get well”. This kind of attitude 
is generally higher among patients with illness. As 
said by the Director of Clinical Research Centre, 
Dr. Goh Pik Pin, “ ... when patients have good 
trustworthy doctors and are in need of new 
therapies they are more willing to subject 
themselves to trials” 16.
However, the researchers were of the 
opinion that doctor-investigators cannot use the 
reason that the patients placed high hopes on them 
for them not to disclose information. Rightfully, the 
special relationship that exist requires doctor-
investigators to disclose full information to patient-
subjects. This is because the doctor-patient 
relationship impedes the ability of the patient to 
make a free choice. A patient usually will wongly 
assume that they will be receiving a treatment 
which their doctor believes to be in their best 
interest by accepting the doctors’ invitation to 
participate in the trial. In actual fact they are 
actually been invited to take part in a trial which is 
designed to yield knowledge for the benefit of the 
future patients and not to meet their individual 
health needs. Thus, the doctor has the responsibility 
to disclose full information to the  patient.
Applying the principle of therapeutic privilege is 
not appropriate in taking informed consent in 
clinical trials; it can cause harm to the patient. The 
privilege will not apply when the patient rejects an 
intervention suggested by physician. Henceforth the
informed consent in clinical trial must be fully 
informed, a stricter standard than required in 
medical treatment.
The researchers were also of the opinion 
that doctor-investigators cannot make an 
assumption that patient-subjects do not have the 
ability to understand the information disclosed to 
them. In a 1998 study, schizophrenic patients 
participating in randomized clinical trials of 
different antipsychotic medications were first given 
informed consent forms to read and sign. The study 
found that the patients were able to understand the 
material in the forms. Even one week later, the 
patients were able to answer most of the questions 
asked about “the study’s procedures and goals, 
patients’ available choices as participants, their 
doctors’ responsibilities to the study, and potential 
ill effects of antipsychotic drugs that were to be 
given in the trial”17. This will be more so if it 
involves a competent patient as a patient-subject.
That is why doctor-investigator cannot deny the 
rights of patient-subjects to get information.
CONCLUSIONS
The aspect of information disclosure in the process 
of obtaining informed consent in clinical trials is 
rather poor and did not fulfill the criterion of good 
medical practice. The doctor-investigators failed to 
disclose full information to patient-subjects. This 
indicated that doctor-investigators failed to 
acknowledge patient-subjects’ protection through 
informed consent. Considering that informed 
consent process is important to ensure protection of 
patient-subject in clinical trials, doctor-
investigators must understand their duty in 
disclosing information better. They must always 
bring to mind that they are no longer allowed to 
withhold information from patients by practising 
the principle of therapeutic privilege once they are 
involved in clinical trials. In other words, once the 
‘doctor’ puts on the hat of a ‘doctor-investigator’ 
by conducting a trial he is responsibled to disclose 
full infomation about the trials particularly the risks 
to the patient-subjects. This study focussed on 
competent patient-subjects; a study on the process 
of taking informed consent in incompetent patient-
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subjects (vulnerable subjects) may be more 
revealing on the frailities of the process and thus 
should be a logical extension of this research. We 
suggest that random monitoring be conducted by 
the research ethics commitees on the process of 
taking informed consent.
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